

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

23<sup>rd</sup> January 2023

Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ	
Mumbai - 400 001	Bandra (East), Mumbai - 400 051	
Dalal Street,	C/1, G block, Bandra Kurla Complex,	
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 <sup>th</sup> Floor, Plot No.	
BSE Limited	National Stock Exchange of India	

Sub: Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of SEBI (LODR) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 39(3) of the SEBI LODR Regulations and in terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2022/8 dated January 25, 2022, the Company has approved issuance of "Letter of Confirmation" on 20<sup>th</sup> January 2023 in lieu of share certificate, which was reported as lost by the following shareholder as under:

Name of Shareholder	Folio No	Old Certificate No.	New Certificate No.	Distinctive Nos.	Shares
LAXMIDAS N PATEL	00075	490	19541	439751 - 440875	1125

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,

## **Gaurang Shah**

*VP – Legal & Company Secretary*